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Abstract
The latest data support the correlation of atherosclerosis and osteoporosis,
indicating the parallel progression of two tissue destruction processes with
increased fatal and non-fatal coronary events, as well as higher fracture risk.
Vitamin D inadequacy associated with low bone mineral density increases fall
and fracture risk, leads to secondary hyperparathyroidism, calcifies coronary
arteries and significantly increases cardiovascular disease. Randomized clinical
trial evidence related to extraskeletal vitamin D outcomes was limited and
generally uninformative. A recent recommendation on vitamin D dietary
requirements for bone health is 600 IU/d for ages 1-70 years and 800 IU/d for
71 years and older, corresponding to a serum 25-hydroxyvitamin D level of at
least 20 ng/ml (50 nmol/l). Further large randomized controlled trials are needed
to reassess laboratory ranges for 25-hydroxyvitamin D in both diseases, in order
to avoid under- and over-treatment problems, and completely clarify the
relationship between atherosclerosis and osteoporosis.
Key words: vitamin D deficiency, low bone density, cardiovascular disease, fracture
risk.
Introduction
Both epidemiological and clinical studies have indicated that patients with
low bone mineral density (BMD) are at significantly greater risk of developing
cardiovascular disease (CVD) as well as unexpected cardiovascular events,
more severe coronary atherosclerosis and vascular calcification [1-4].
Pathophysiological mechanisms that connect atherosclerosis and
osteoporosis (OP) are complex and could be dependent and/or
independent of the production of vitamin D (Vit D). A low level of Vit D
decreases BMD, influences neuromuscular dysfunction (weakness of
proximal muscles), increases the risk of falls and fractures, and stimulates
the renin-angiotensin system, leading to the development of hypertension
(HTA), left ventricular hypertrophy, and coronary artery calcification
associated with congestive heart failure [5]. 
A recent review of randomized trials evaluating the effect of greater
doses and higher achieved 25-dihydroxyvitamin D [25(OH)D] levels on
health outcomes concluded that the optimal benefit of Vit D for CVD (as
well as cancer) was obtained at 25(OH)D concentrations of 75-110 nmol/l
(30-44 ng/ml). These levels can best be obtained with oral daily doses of
Vit D in the range of 1,800 to 4,000 IU [6].
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Cardiovascular disease and osteoporosis
At present, growing evidence indicates the
existence of a correlation between CVD and OP
(fractures), irrespective of age [1-3]. These clinical
conditions, linked by numerous common patho  -
physiological mechanisms and risk factors, are
asymptomatic in the early clinical stages. It is a fact
that 200 million people have been diagnosed with
OP, whereas epidemiological studies concerning the
number of atherosclerosis sufferers do not exist.
The socio-economic consequences of both these
diseases are very important bearing in mind the
facts that OP is the second highest world health
problem after CVD, and this number will increase
with the growth of the elderly population over the
next decades.
Cardiovascular disease and OP together account
for most of the morbidity and mortality in our aging
population despite significant improvements in
treatment. Osteoporotic post  menopausal women
are at significantly greater risk of CVD, cardio  -
vascular mortality and bone fractures than age-
matched controls [4, 5]. Patients with lower bone
density and OP also have higher lipid levels, more
severe coronary atherosclerosis, and a greater risk
of stroke death. The common finding of simul  -
taneous vascular calcification and OP in individual
patients suggests that local tissue factors govern the
regulation of biomineralization [7]. Serum 25(OH)D
levels are inversely associated with important CVD
risk factors. The latest results indicate a strong and
independent relationship of 25(OH)D deficiency with
prevalent CVD in a large representative sample of
the US adult population [8].
The following facts clearly reflect the association
between these two diseases. Risk factors for
vascular disease, such as dyslipidaemia, systemic
arterial HTA, diabetes mellitus, and hyper  -
homocysteinaemia, have been associated with
a higher incidence of low bone mineral density. In
addition, there is evidence indicating the action of
antiresorptive drugs on the reduction of
cardiovascular risks and the effect of statins,
antihypertensives and insulin on bone mass
increase [1]. The connection between low values of
BMD and the risk of fractures is similar to the
correlation between HTA and cardiovascular events.
It has been established that myocardial infarction
is the cause of approximately 50% of all fatalities. 
Fracture and pain assessment 
in osteoporotic patients
A myocardial infarction is often the first clinical
manifestation of atherosclerosis, as well as fractures
in patients with low BMD. Pain is the first clinical
manifestation of OP and atherosclerosis. It can be
seen that 30-40% of women aged over 50 years
have low BMD and coronary disease, with the
prevalence of carotid atherosclerosis of 42% in the
observed population [9]. Of all postmenopausal
women, 30% have OP of the hip, lumbosacral spine
(LS), or in the distal segment of the radius [10]. More
than 50% have had a previously diagnosed fracture
of the proximal part of the femur, vertebral fracture,
proximal part of the humerus, a distal segment of
the forearm or of the pelvis [10]. With regard to the
latest scientific knowledge, reference values of BMD
for men have been shown to be on the same level
of fracture risk as amongst women, which can also
be linked to the risk of coronary diseases in both
genders [11].
In OP, pain is a consequence of a low energy
fracture or spontaneous fracture which points to
late diagnosis. It is a remarkable fact that about
50% of women aged over 50 years had no idea they
were suffering from vertebral fractures. Therefore,
it is of particular importance for everyday clinical
practice to recognise them early, because the
intensity of pain is not in correlation with the
presence and degree of vertebral fracture, and often
is not linked with a known mechanical load.
Moreover, some of these women felt no pain at all.
Indeed, only 33% of vertebral fractures are
considered to be diagnosed in clinical practice. On
the other hand, not all patients suffer an OP
diagnosed fracture during their lives, but 30-40%
of patients with osteopenia had fractures as well
as 10-20% of patients with a T-score within the
range of reference values [10]. Fracture risk
reduction correlates neither with the degree of
raised BMD nor with the same BMD in relation to
various geographical areas. Until recently it was
considered that 70-80% of fractures were
determined by BMD. Now, it is known that BMD, by
around 30%, Not clear is one among a number of
risk factors in the assessment of bone quality and
fracture risk. Genetic factors, however, dominate
all risk factors by over 60%. This position is
supported by a cohort study which investigated the
frequency of fractures in OP . Only 46% of women
with fractures had BMD in the OP level [12]. The
incidence of typical fractures in OP is low and varies
in different fracture locations over a wide spectrum
ranging from less than 10% to 44% [13]. Moreover,
cases with a T-score within the level of OP at one
measurement point do not have to have OP
anywhere else. Therefore, a large number of
measurement points raises the probability of better
assessing fracture risk, as concluded in some
published articles [11, 14].
In the latest recommendations regarding
evaluation for initiating therapy, great importance
is given to assessing future fracture risk 
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(www.shef.ac.uk./FRAX) using previous X-ray
evaluations for fractures of the vertebral column,
and BMD [15].
Association of atherosclerotic processes with
bone metabolism and osteoporosis
The effect of atherosclerosis on bone metabolism
and the development of OP was established owing
to investigations confirming that a decreased value
of BMD is a good mortality predictor during
cardiovascular occurrences and coronary disease in
postmenopausal women and men older than 50
years of age. In fact, the connection between CVD
and OP exists not only in the process of aging.
A connection has been confirmed between the
decreased value of BMD, and unexpected cardio  -
vascular mortality, as well as the incidence of 
CVD occurring in Caucasian women, but not in 
men [3, 4].
A correlation exists between OP and athero  -
sclerosis regardless of age, body mass index (BMI)
and cardiovascular risks. Cases of low BMD of the
hip have a higher risk of CVD mortality in both
genders [16].
The inverse correlation of cardiovascular
calcification and loss of bone calcium indicates that
this is the parallel progression of two processes of
tissue destruction. Postmenopausal women with
atherosclerotic changes of the abdominal aorta, in
comparison with those having no vascular calci  -
fication, have a significantly decreased value of
BMD at the lumbar spine and hip, higher hip
fracture risk (× 2.9) and vertebral fracture risk (× 4.8),
as well as a higher incidence of fatal and non-fatal
coronary events [17].
Pathophysiological mechanisms connecting
atherosclerosis and osteoporosis are complex and can
be dependent or independent of the production of
vitamin D. Hyperproduction of inflammatory markers
such as C-reactive protein, interleukin-1 (IL-1),
interleukin-6 (IL-6) and tumour necrosis factor-α
(TNF-α) can be considered risk factors and some
are directly related to the severity of atherosclerosis,
with pre-resorption effects and the stimulation of
osteoclastogenesis [1].
Association of lipid fraction levels 
with osteoblast and osteoclast function 
An increase of low density lipoprotein cholesterol
(LDL-C) and a reduction of high density lipoprotein
cholesterol (HDL-C) levels have been associated
with low BMD in postmenopausal women [18].
Lipid oxidation products such as minimally
oxidized LDL-C promote arterial calcification, and
its accumulation in the subendothelial space of
skeletal bone arteries inhibits bone formation [19].
The hyperproduction of oxidized low density
lipoprotein fraction of cholesterol stimulates
atherogenesis and activates osteoblasts in the
arterial pool, leading to the calcification of arterial
plaque. However, the published results are con  -
troversial. It has been shown that plasma 
LDL-C level inversely correlated with BMD values,
while low plasma triglyceride (TG) levels were
associated with the presence of vertebral fractures
in postmenopausal women [18-22].
Some studies found no association between
serum lipid concentrations and BMD [23] and other
studies found even a positive relationship between
them [22-25].
The study of Sivas et al. [22] showed that serum
lipids have an impact on vertebral fracture
existence, rather than BMD alterations. The total
cholesterol (TC), TG and LDL-C levels were lower in
postmenopausal women who had at least one
vertebral fracture. TC level was the strongest factor
affecting vertebral fracture existence. And an
increase of 1 mg/dl TC decreased the risk of
vertebral fracture by 2.2%. In the study of Jeong et
al. [26] after adjustment for clinical and laboratory
covariates, the authors found a weak positive
association between HDL-C and BMD at the lumbar
spine only in postmenopausal women. This result
is in accordance with the work of Yamaguchi et al.
[18] but opposite to the results of the study by
Adami et al. [24], in which worse lipid profiles (lower
HDL-C and higher LDL-C or TG) were associated
with higher bone mass, although they could not
provide a documented explanation. In conclusion,
the correlation between lipid profile and BMD was
neither consistent at all bone sites [26], nor from
study to study. Further studies are needed to clarify
this relationship and the underlying mechanism.
The artery wall contains endothelial cells
capable of differentiation into osteoblasts, following
the same stages of differentiation as occur in bone-
derived osteoblasts, and ultimately producing bone
mineral. So, the same oxidized lipids that induce
atherosclerosis also induce mineralization and
differentiation of the osteoblastic cells in the artery
wall. Consistent with this finding, hyperlipidaemia
is associated with vascular calcification in mice [7].
On the other hand, hyperproduction of LDL-C and
lipid accumulation in the subendothelial matrix
would be expected to inhibit differentiation of
osteoblasts from preosteoblasts and enhance
osteoclastic differentiation and activity, which lead
to decreased bone density. Oxidized lipids induce
endothelial expression of monocyte chemotactic
factors and the monocyte colony-stimulating factor
(M-CSF), a potent inducer of osteoclastic dif  -
ferentiation and differentiation of osteoclast
precursor cells, which consequently promote bone
resorption [18, 19]. At the same time, oxidized 
LDL-C molecules act in the suppression of terminal182 Arch Med Sci 2, April / 2011
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differentiation of stromal cells into osteoblasts,
while HDL inhibits cytokines responsible for the
osteogenic differentiation of vascular cells [27]. The
mechanism of arterial calcification resembles the
process of osteogenesis, involving various cells,
proteins and cytokines that lead to tissue
mineralization [28]. Clinical studies also support
the role of lipids in both vascular calcification and
OP . Lipid-lowering agents reduce coronary vascular
calcification in patients, where the degree of
improvement follows in direct relation to the
degree of lowered lipids [29]. Lipid-lowering agents
also enhance bone mineralization in rodents [30]
and humans [31] and may reduce the incidence of
osteoporotic fractures in patients [32-34]. These
effects on bone were originally attributed to
a direct effect of the specific class of lipid-lowering
agents used, hydroxymethylglutaryl-coenzyme A
(HMG-CoA) reductase inhibitors (statins). It is
possible that statins may directly protect bone [20].
However, it is not yet possible to distinguish
whether the improvement in bone density and
reduction in fracture risk are due to lipid lowering
or to a direct effect of statins on bones. It is
notable that bisphosphonates, leading agents for
OP, also reduce LDL cholesterol and increase 
HDL cholesterol levels in humans [35]. Experimental
studies using animal models of vascular
calcification have demonstrated that bisphospho  -
nates completely inhibit arterial and cardiac
calcification in mice [36]. The protective effect of
bisphosphonates has been attributed to their
direct action on the vessel wall by sensitizing
macrophages to undergo apoptosis, preventing
foam cell formation by inhibiting the uptake of 
LDL-C and affecting cell replication [37]. Also,
a recent study showed that bisphosphonates
induce inflammation and rupture of atherosclerotic
plaques in apolipoprotein-E null mice [38]. These
data support the concept that lipids contribute to
both vascular calcification and OP . Osteopenia and
OP correlate positively with atherosclerosis,
vascular calcification, and cardiovascular events,
with some evidence of age independence [3]. Thus,
plasma lipids may be related to bone mass and
bone fragility, and could be the common factor
underlying both OP and vascular calcification,
which suggests that these diseases share common
pathophysiological pathways [27]. In human
calcified atherosclerotic plaque, as in bone tissue,
the same modulators of bone metabolism can be
detected: osteopontin (OPN), osteocalcin, matrix
Gla protein (MGP), osteonectin, osteoprotegerin
(OPG), bone morphogenetic protein (BMP),
receptor activator of nuclear factor κB ligand
(RANKL), inflammatory cytokines, type 1 collagen,
proteo  glycan and nitric oxide (NO). The dysfunction
of endothelial synthase (e-NOS) of NO is present
in both processes [18, 39, 40]. Several mechanisms
of vascular injury have been proposed for
homocysteine, including a reduction in nitric oxide,
endothelial dysfunction, increased platelet ag  -
gregation, and proliferation of vascular smooth
muscle cells, among others [27].
Furthermore, bone and coronary arteries are
target organs for oestrogens. Vitamin D directly
affects oestrogen synthesis by regulating the
activity of aromatase in osteoblasts [41] and
oestrogen half-life by regulating 17 hydroxysteroid
dehydrogenase in keratocytes [42]. Woman after
the menopause demonstrate accelerated bone loss.
Also, the beneficial effects of oestrogens on the
cardiovascular system and atherosclerosis are well
established [19, 43, 44].
Homocysteine is a possible risk factor for
atherosclerosis [45]. Homocystinuria is a genetically
inherited disease which is characterised by elevated
plasma homocysteine concentrations. Its clinical
manifestations, apart from skeletal disorders and
OP, include a tendency towards premature
atherosclerosis and thromboembolism. There is also
evidence that postmenopausal woman with
a heterozygous mutation in methylene  tetra  -
hydrofolate reductase (MTHFR) and, therefore,
hyperhomocysteinaemia demonstrate a decrease
in BMD. This supports the hypothesis that
homocysteine participates in the interaction
between oestrogen and bone metabolism [19, 46]. 
Also patients with OP and atherosclerosis exhibit
insufficient vitamin K levels. Vitamin K is a cofactor
required to convert the amino acid glutamate into
gamma-carboxyglutamate, or Gla-proteins [47]. Gla-
proteins regulate physiological processes controlled
by calcium. These include blood coagulation
(clotting) and bone mineralization. Accordingly, Gla-
proteins are critical to the formation and re  -
plenishment of bone tissue. Unless these proteins
are modified by vitamin K, they cannot properly
form the matrix in which calcium and phosphorus
bind together to make solid, well-mineralized bone.
Vitamin K has been shown to stimulate new bone
formation and reduce the incidence of vertebral
fractures [48, 49]. The Gla-protein osteocalcin,
normally present in bone, has been found in
calcified atherosclerotic plaque lesions, and
production of this protein is pathologically up  -
regulated in people with atherosclerosis [50]. At the
same time, another vitamin K-dependent Gla-
protein known as matrix Gla-protein (MGP),
normally found in healthy arterial walls, is a strong
inhibitor of vascular calcification [51, 52]. In other
words, by increasing MGP in the arterial walls,
vitamin K protects against the calcification-inducing
effects of osteocalcin. Therefore, vitamin K
deficiency is also a confounder in the OP/CVD
relationship.Arch Med Sci 2, April / 2011 183
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Potential pathophysiological mechanisms
which determine the role of vitamin D 
in atherosclerosis and osteoporosis 
Except for the association of Vit D deficiency with
the prevalence of traditional CVD risk factors,
emerging data suggest a more direct role of Vit D
in the development of atherosclerotic disease [53]. 
Several pathophysiological mechanisms which
determine the role of Vit D in athero  sclero  -
sis/cardiovascular disease and OP have been
proposed and are summarised in Table I.
Serum concentration of 25(OH)D, the main
circulatory metabolite of Vit D, was accepted in 1997
by the Panel on Calcium and Related Nutrients 
of the Food and Nutrition Board (IOM-NAS) as
a baro  meter for the status of Vit D. 25-hydro  -
xyvitamin D, as a substrate of renal and extra-renal
production of 1,25-dihydroxyvitamin D, reflects the
total production (endogenous and exogenous
sources) of Vit D. The presence of the physiological
active metabolite 1,25(OH)2D- 1,25 dihydroxyvitamin
D3 shows that Vit D has a hormonal effect. Vita  -
min D receptors (VDR) are present in many different
tissues, such as brain, breast, immune cells, muscle
tissue, parathyroid glands, cardiomyocytes, vascular
endothelial and vascular smooth muscle cells,
endothelial cells of colon mucosae, as well as
malignant colon cells [54, 55]. 
The expression of VDR in vascular endothelial
and smooth muscle cells converts 25-OH Vit D from
a biologically inactive form (in a physiological
concentration) by hydroxylation in the kidneys of
1-α hydroxylase into 1,25(OH)2D (dihydroxycho  -
lecalciferol), the active metabolic form of Vit D,
regulated by parathyroid hormone (PTH) secretion.
Dihydroxycholecalciferol regulates the renin-
angiotensin axis by directly suppressing the renin
gene. 25(OH)D binds with Vit D binding protein
(DBP) and is transported to the kidneys through the
circulation [54].
Kidney activity may decrease during ageing,
parallel with decreased renal function, and a similar
decrease in DBP, as well as a lessening of albumin
in sera. Subsequently, low levels of 25(OH)D in older
people with hip fractures may be a consequence of
decreased DBP as the active metabolites of Vit D
are mainly linked to DBP .
An inadequacy of Vit D directly promotes the
development of HTA, leads to the hyperproduction
of PTH and, consequently, secondary hyper  -
parathyroidism, cardiomyocyte hypertrophy and
vascular remodelling – ventricular hypertrophy. Also,
this process influences inflammation by stimulating
the release of cytokines from smooth muscle
vascular cells [56]. Vitamin D inhibits vascular
calcification by blocking the release of inflammatory
Atherosclerosis/cardiovascular disease Osteoporosis
• VDR polymorphisms (especially Bsml)
• Presence of α-hydroxylase enzyme in endothelium 
and VSMC
• Presence of VDRs in endothelium and VSMC
• PTH suppression
• Regulation of renin-angiotensin-aldosterone system
• Presence of VDRs in immune cells (T-lymphocytes, 
macrophages)
• Downregulation in the production of inflammatory 
markers (CRP) and several cytokines (IL-1, IL-2, IL-6, 
IL-12, interferon-γ, TNF-α, TNF-β)
• Suppression of EGF in VSMC
• Induction of prostacyclin in VSMC
• Downregulation of PAI-1, thrombospondin-1 
and thrombomodulin
• Suppression of foam cell formation
• Reduced gene expression of bone-forming cells 
in the aorta 
VSMC – vascular smooth muscle cells, VDR – vitamin D receptor, PTH – parathyroid hormone, CRP – C-reactive protein, IL – interleukin, 
TNF – tumour necrosis factor, EGF – epidermal growth factor, PAI-1 – plasminogen activator inhibitor-1, VDR – Vit D receptor, DBP – Vit D binding
protein, 1,25(OH)2D – dihydroxycholecalciferol
Adapted from: Anagnostis P, Athyros VG, Admidou F, Florentin M, Karagiannis A. Vitamin D and cardiovascular disease: a novel agent for reducing
cardiovascular risk? Curr Vasc Pharmacol 2010; 8: 720-30
Table I. Potential pathophysiological mechanisms of vitamin D in atherosclerosis/cardiovascular disease and
osteoporosis 
• VDR polymorphisms 
• Decline in renal 1,25(OH)2D production
• Regulation of PTH secretion
• Decline in intestinal VDR
• Decline in DBP
• Diminished renal response to PTH and reduced 
intestinal calcium absorption
• Presence of VDRs in immune cells 
(T-lymphocytes, macrophages) 
• Downregulation in the production of inflammatory 
markers and several cytokines 
• Effect on oestrogen synthesis:
– regulating the activity of aromatase in osteoblasts,
– regulating 17 hydroxysteroid dehydrogenase184 Arch Med Sci 2, April / 2011
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cytokines and adhesion molecules and preventing
abnormal changes in smooth muscle cells in vessel
walls [57]. Accordingly, low vitamin D levels are
associated with increased risk for development of
the coronary arterial calcifications seen in
atherosclerosis [58]. 
An inadequacy of Vit D in serum decreases the
absorption of calcium (Ca) in the intestine, causes
low values of serum Ca and compensatory
hypersecretion of PTH and 1,25(OH)2. This results in
mobilising Ca and phosphorous (P) from bones, in
order to maintain the optimal level of Ca and P in
sera for bone turnover, metabolic processes and
neuromuscular functions. Nevertheless, as a result
of the compensatory mechanisms a serum level of
25(OH)D may be maintained at reference values
despite hypocalcaemia [59]. The disturbance of
homeostatic mechanisms influences both skeletal
and extraskeletal metabolic processes. An inadequacy
of Vit D lowers BMD, gives rise to neuromuscular
dysfunction – proximal muscular weakness –
myopathy, sarcopenia, and increased risk of falls,
although these are reversible processes [56].
Reduced levels of Vit D have a negative effect
on the musculoskeletal system and, by increasing
susceptibility to arterial calcification, cause an
excess of cardiovascular risk factors. Clinical studies
confirm that Vit D deficiency influences the activity
of renin in plasma, which leads to HTA – via
increased arterial resistance, calcification of the
coronary arteries and a significant rise in CVD [60].
Vitamin D regulation of renin expression was
independent of calcium metabolism and
1,25(OH)2D3 markedly suppressed renin trans  -
cription by a VDR-mediated mechanism in cell
cultures. Hence, 1.25(OH)2D3 is a novel negative
endocrine regulator of the renin-angiotensin
system. Its apparent critical role in electrolytes,
volume, and blood pressure homeostasis suggests
that Vit D analogues could help prevent or
ameliorate HTA [57].
Vitamin D deficiency is associated with congestive
heart failure and blood levels of inflammatory
factors, including C-reactive protein and cytokines
such as interleukin-10. Cytokines have recently been
identified as having an important role in
atherogenesis [61]. Vitamin D analogues have been
shown to inhibit the production of several
proinflammatory cytokines while stimulating the
effects of Th2 lymphocytes, leading to a reduction
in matrix metalloproteinase and, thereby, reducing
plaque production or instability [62].
Secondary hyperparathyroidism, as a conseq  -
uence of Vit D insufficiency, also has negative
implications for the cardiovascular system and bone
metabolism. Living at higher latitudes increases the
risk of HTA, CVD and prevalence of Vit D
insufficiency [63].
Recent evidence suggests that Vit D intakes
above current recommendations may be associated
with better health outcomes. However, optimal
serum concentrations of 25(OH)D for skeletal and
extraskeletal functions are different in various
published investigations. Nevertheless, it can be
concluded that a daily dose of 400 IU of Vit D does
not adequately reduce fracture risk [64].
A review by Roux et al. [64] applied the risk
assessment method used by the Food and Nutrition
Board to update the safe tolerable upper intake level
(UL). For Vit D the method focuses on the risk of
hypercalcaemia. The last statement concerning the
upper limit (UL) indicates the level above which there
is risk of adverse events. The UL is not intended as
a target intake; rather, the risk for harm begins to
increase once intakes surpass this level [65].
In previous reviews the general conclusion was
that the UL for Vit D consumption by adults should
be 10 000 IU/d [66]. This indicates that the margin
of safety for Vit D consumption for adults is > 10
times any current recommended intake [67]. The
1997 UL for Vit D was 2000 IU/d for most age
groups. The starting point for the current UL for
vitamin D was 10,000 IU/d, because lower intakes
have been linked to neither hypercalcaemia nor
acute toxicity. However, this value was corrected
due to uncertainty, given that toxicity is not the
appropriate basis for a UL that is intended to reflect
long-term chronic intake and be used for public
health purposes. The correction was based on
chronic disease outcomes and all-cause mortality,
as well as emerging concerns about risks at serum
25(OH)D levels above 50 ng/ml (125 nmol/l). Thus,
the Committee followed an approach to maximize
public health protection and the UL for Vit D is now
4000 IU/d [65].
For all endpoints, the most advantageous serum
concentrations of 25(OH)D begin at 75 nmol/l 
(30 ng/ml), with the best being between 90 nmol/l
and 100 nmol/l (36-40 ng/ml). In most people, these
concentrations cannot be reached with the
currently recommended daily intakes of 200 IU and
600 IU Vit D for younger and older adults,
respectively. Several studies suggest that many
older people will not achieve optimal serum
25(OH)D concentrations during the summer
months, which suggests that Vit D supplementation
should be independent of season in older persons
[68]. An intake for all adults of ≥ 1000 IU (25 μg) 
Vit D3 (cholecalciferol)/daily is needed to bring 
Vit D concentrations up to 75 nmol/l (30 ng/ml) in
at least 50% of the population [69]. An exploratory
analysis of the heterogeneity demonstrated
a significant positive association comparable to an
increase of 1-2 nmol/l in serum 25(OH)D for every
100 additional units of Vit D although heterogeneity
remained after adjusting for dose [70].Arch Med Sci 2, April / 2011 185
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A reduction of risk of falls and fractures, without
adverse effects, was proved for the dose 700-1000 IU
with Ca supplementation (1000-1200 mg elementary
Ca daily) [71]. This dose of Vit D has an anti-
inflammatory effect and blocks plaque calcification
in arterial blood flow. Toxic doses lead to medical  -
cinosis, which is a reversible process [57]. 
Furthermore, calcium supplementation by itself
did not reduce risk of fractures [72]. As noted in the
Institute of Medicine (IOM) review [65], in the
analysis of NHANES data with more than 9,000
subjects, calcium intake was associated with hip
bone density only among women with low 25(OH)D
levels; in all other groups there was no relation
between calcium intake and bone density. In
contrast, 25(OH)D levels were consistently and
positively associated with hip bone density [73].
Thus, with adequate 25(OH)D levels or sufficient
Vit D intake, higher calcium intakes may not be
correlated with bone health. In sum, calcium
recommendations could be adjusted downward
with Vit D supplementation; they could also possibly
be adjusted downward for safety reasons. The IOM
states that more data regarding the interaction of
Vit D and calcium on bone health are needed and
no recommendation was provided on their
combination [74].
In other studies it was found that the level of
25(OH)D below 30 ng/ml (75 nmol/l) was strongly
associated with suboptimal Ca absorption.
A reduction of fracture incidence was observed
when the level of 25(OH)D was above 75 nmol/l as,
due to the beneficial effect on bone metabolism
and muscle strength, there was a resulting lower
incidence in the number of falls [75]. Also, it was
noted that when the level of 25(OH)D was in the
range 27.5-37.5 nmol/l, the PTH level progressively
rose [7].
In patients with HTA and a value of 25(OH)D 
< 27.5 nmol/l (15 ng/ml), the risk of unexpected
cardiovascular events was doubly increased. Only
10% of patients examined in the cohort study had
25(OH)D > 75 nmol/l or 30 ng/ml [17, 55].
Recent data (a meta-analysis of trials totalling
12 000 participants) showed that calcium supple  -
ments (without coadministered Vit D) are
associated with an increased risk of myocardial
infarction by about 30% [76].
It is now clear that a value of 25(OH)D of 
75-100 nmol/l (30-40 ng/ml) is optimal for 
both bone metabolism and extraskeletal
manifestation. Insufficiency was determined at
25(OH)D 25-75 nmol/l (10-30 ng/ml) and deficiency
at 25(OH)D < 25 nmol/l (< 10 ng/ml). Complete
deficiency leads to rickets in children and
osteomalacia in adults [7, 56].
Also, studies of the health benefits of raising se  -
rum 25(OH)D levels to 100-112.5 nmol/l (40-45 ng/ml)
at the population level on the basis of serum
25(OH)D level-disease outcome responses estimate
about a 15% reduction in the all-cause mortality
rate and a reduction in the economic burden of
disease treatment of 10-20% [77, 78]. Another study
estimated that if all those in the United States were
to double their solar ultraviolet-B irradiance to raise
their serum 25(OH)D level to 112.5 nmol/l (45 ng/ml)
the net result could be as many as 400,000 reduced
deaths compared with only 11,000 increased deaths
from melanoma and other skin cancer [79].
The Institute of Medicine (IOM) Committee
concluded [65] that the evidence of Vit D or Ca
reducing the risk of non-skeletal chronic disease
outcomes was inconsistent, inconclusive, and did
not meet criteria for establishing cause-and-effect
relationships. Randomized trial evidence was
sparse, and few trials assessed these outcomes as
primary prespecified endpoints. Moreover, emerging
evidence suggested a curvilinear or U-shaped curve
for several outcomes related to Vit D, including
cardiovascular disease, vascular calcification, falls,
and frailty [56], with lower risk at moderate levels
and increased risk at both low and high levels of
25(OH)D [65]. However, the data used to suggest
that higher serum 25(OH)D levels are associated
with adverse health outcomes for several types of
cancer, CVD, and all cause an increased mortality
rate, are inadequate representations of findings in
the literature or are, essentially, taken out of
context. When other findings are combined with
those findings, one finds reduced disease rates with
increasing Vit D indices [80] .
In the same report by the IOM Committee, based
on bone health Recommended Dietary Allowances
(RDAs; covering the requirements of ≥ 97.5% of the
population), were given calcium intake ranging 
from 700 to 1300 mg/d for life-stage groups from
1 year of age. For Vit D, RDAs of 600 IU/d for ages
1-70 years and 800 IU/d for ages 71 years and older,
corresponding to a serum 25-hydroxyvitamin D level
of at least 20 ng/ml (50 nmol/l), meet the
requirements of at least 97.5% of the population.
The 2011 Vit D Dietary Reference Intakes (DRIs) are
based primarily on the integration of bone health
outcomes with evidence concerning 25(OH)D levels,
which suggest that levels of 16 ng/ml (40 nmol/l)
meet the needs of approximately half the
population, and levels of at least 20 ng/ml 
(50 nmol/l) meet the needs of at least 97.5% of the
population (akin to the RDA). Intakes of Vitamin D
required to achieve these 25(OH)D concentrations
are based on a simulation of available data 
covering all ages under conditions of minimal sun
exposure [65].
But, in the last “Comment on the IOM Vitamin D
and Calcium Recommendations” by Heike Bischoff-
Ferrari and Walter Willett [74] the authors present186 Arch Med Sci 2, April / 2011
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the opinion that 25(OH)D levels far beyond 
50 nmol/l (20 ng/ml) in younger and older adults
are needed for optimal bone health, suggesting that
the IOM threshold recommendation is too low [81].
In contrast to the IOM report, the IOF recommended
in their 2010 position paper on Vit D a threshold of
75 nmol/l for optimal fall and fracture reduction and
recommended 800 to 1,000 IU of Vit D per day for
seniors aged 60 years and older [82, 83].
Further studies are necessary to define the
relationship between atherosclerosis and OP with
proved common risk factors including race and
genetic and molecular determinants. The correlation
between lipid profile and BMD was consistent
neither at all bone sites, nor from study to study. 
Existing evidence of extraskeletal Vit D outcomes
from randomized clinical trials is limited and
generally uninformative. Large randomized con  -
trolled trials and public health investigations are
needed to reassess laboratory ranges for 
25-hydroxyvitamin D in both diseases, in order to
avoid under- and overtreatment problems.
Education of clinicians and patients is one of the
most important tasks in the prevention of
atherosclerosis and osteoporosis. Raising awareness
about maintaining a good quality of life will lead to
a decrease in the risk of fractures, myocardial
infarction and mortality. Consequently, additional
studies are needed to determine the exact
mechanisms shared by atherosclerosis and
osteoporosis and clarify not only this relationship
but also the underlying mechanism.
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